Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(4):251; doi:10.1093/jnci/93.4.251
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 4, 251, February 21, 2001
© 2001 Oxford University Press

IN THIS ISSUE

Human Papillomavirus and Cervical Cancer

Human papillomavirus (HPV) infection is now considered the main cause of cervical cancer. Three papers in this issue of the Journal focus on extending knowledge of this causal relationship and its implications for prevention efforts.

Harro et al. (p. 284) conducted a double-blind, placebo-controlled, dose-escalation trial in healthy adults to evaluate the safety and immunogenicity of an HPV type 16 (HPV16) vaccine composed of virus-like particles containing the major structural viral protein L1. Volunteers received 10-µg or 50-µg doses of the vaccine given without or with alum or MF59 as adjuvants at 0, 1, . . . [Full Text of this Article]

Better Treatment for Small-Cell Lung Cancer

Trends in U.S. Lung Cancer Mortality

Hypoxia-Inducible Factor-1{alpha} and Breast Carcinogenesis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?